STOCK TITAN

[SCHEDULE 13G/A] Allakos Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Three reporting persons filed a Schedule 13G/A for Allakos Inc. (Common Stock). The filers—Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin—report zero shares beneficially owned and 0.00% ownership of the class. The statement shows no sole or shared voting or dispositive power attributed to any reporting person.

The calculation of the percentage is based on the issuer's reported share count of 90,376,972 common shares outstanding. The filing includes a joint filing statement where the undersigned agree to file future amendments on behalf of each other and confirm responsibility for their respective disclosures.

Tre persone che presentano segnalazioni hanno depositato uno Schedule 13G/A per Allakos Inc. (Common Stock). I presentatori — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; e David Kroin — dichiarano zero azioni possedute a titolo di beneficiario e 0,00% di partecipazione nella classe. La dichiarazione indica nessun potere di voto o di disposizione, né in via esclusiva né congiunta attribuito a qualsiasi persona che presenta la segnalazione.

Il calcolo della percentuale si basa sul numero di azioni ordinarie in circolazione riportato dall'emittente di 90.376.972. Il deposito include una dichiarazione congiunta in cui i sottoscritti concordano di presentare future modifiche per conto reciproco e confermano la responsabilità per le rispettive comunicazioni.

Tres declarantes presentaron un Schedule 13G/A para Allakos Inc. (Common Stock). Los presentantes — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; y David Kroin — informan cero acciones en propiedad beneficiaria y 0,00% de propiedad de la clase. La declaración muestra ningún poder de voto ni de disposición, ni en forma exclusiva ni compartida atribuido a ninguna persona declarante.

El cálculo del porcentaje se basa en el recuento de acciones informado por el emisor de 90.376.972 acciones ordinarias en circulación. La presentación incluye una declaración conjunta en la que los abajo firmantes acuerdan presentar futuras enmiendas en nombre de los demás y confirman la responsabilidad por sus respectivas divulgaciones.

세 명의 신고인이 Allakos Inc.(보통주)에 대해 Schedule 13G/A를 제출했습니다. 제출인들 — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; 및 David Kroin — 은 실질적으로 보유한 주식 수 0주 및 해당 종목에 대한 소유 지분 0.00%를 보고했습니다. 해당 신고서에는 어떠한 신고인에게도 단독 또는 공동의 의결권이나 처분권이 부여되지 않음으로 표시되어 있습니다.

지분 비율의 계산은 발행인이 보고한 90,376,972주의 보통주 유통주식수를 기준으로 합니다. 제출 문서에는 이하 서명인들이 향후 수정서를 서로를 대신하여 제출하기로 합의하고 각자의 공시 책임을 확인하는 공동 제출 진술서가 포함되어 있습니다.

Trois déclarants ont déposé un Schedule 13G/A pour Allakos Inc. (actions ordinaires). Les déclarants — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; et David Kroin — déclarent aucune action détenue à titre bénéficiaire et 0,00% de propriété de la catégorie. La déclaration indique qu'aucun pouvoir de vote ni de disposition, ni en propre ni partagé, n'est attribué à l'un quelconque des déclarants.

Le calcul du pourcentage est basé sur le nombre d'actions ordinaires en circulation communiqué par l'émetteur, soit 90.376.972. Le dépôt comprend une déclaration conjointe par laquelle les soussignés conviennent de déposer à l'avenir des amendements au nom les uns des autres et confirment leur responsabilité quant à leurs divulgations respectives.

Drei meldepflichtige Personen reichten ein Schedule 13G/A für Allakos Inc. (Common Stock) ein. Die Meldenden — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; und David Kroin — geben keine zuvorteilhaft gehaltenen Aktien und 0,00% Eigentum an der Aktienklasse an. Die Erklärung weist aus, dass keine alleinige oder gemeinsame Stimm- oder Verfügungsgewalt einer meldenden Person zugerechnet wird.

Die Prozentberechnung basiert auf der vom Emittenten gemeldeten Anzahl von 90.376.972 ausstehenden Stammaktien. Die Einreichung enthält eine gemeinsame Einreichungserklärung, in der die Unterzeichner vereinbaren, künftige Nachträge füreinander einzureichen und die Verantwortung für ihre jeweiligen Angaben bestätigen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Schedule 13G/A shows the reporting group holds no economic or voting stake in ALLK, so no ownership-driven influence.

This disclosure indicates Deep Track entities and David Kroin do not currently hold, vote, or dispose of any Allakos common shares, reported as 0 shares (0.00%) based on 90,376,972 shares outstanding. For investors, the filing confirms absence of a passive ownership stake from these parties and removes potential near-term ownership-based governance influence. The joint filing clause merely allocates amendment responsibilities among the filers.

TL;DR: Governance impact is neutral—no shared or sole voting/dispositive authority is reported by these filers.

The Schedule 13G/A classifies the reporting persons with types including IA, OO, CO, HC, IN where applicable, but records zero voting and dispositive powers

Tre persone che presentano segnalazioni hanno depositato uno Schedule 13G/A per Allakos Inc. (Common Stock). I presentatori — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; e David Kroin — dichiarano zero azioni possedute a titolo di beneficiario e 0,00% di partecipazione nella classe. La dichiarazione indica nessun potere di voto o di disposizione, né in via esclusiva né congiunta attribuito a qualsiasi persona che presenta la segnalazione.

Il calcolo della percentuale si basa sul numero di azioni ordinarie in circolazione riportato dall'emittente di 90.376.972. Il deposito include una dichiarazione congiunta in cui i sottoscritti concordano di presentare future modifiche per conto reciproco e confermano la responsabilità per le rispettive comunicazioni.

Tres declarantes presentaron un Schedule 13G/A para Allakos Inc. (Common Stock). Los presentantes — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; y David Kroin — informan cero acciones en propiedad beneficiaria y 0,00% de propiedad de la clase. La declaración muestra ningún poder de voto ni de disposición, ni en forma exclusiva ni compartida atribuido a ninguna persona declarante.

El cálculo del porcentaje se basa en el recuento de acciones informado por el emisor de 90.376.972 acciones ordinarias en circulación. La presentación incluye una declaración conjunta en la que los abajo firmantes acuerdan presentar futuras enmiendas en nombre de los demás y confirman la responsabilidad por sus respectivas divulgaciones.

세 명의 신고인이 Allakos Inc.(보통주)에 대해 Schedule 13G/A를 제출했습니다. 제출인들 — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; 및 David Kroin — 은 실질적으로 보유한 주식 수 0주 및 해당 종목에 대한 소유 지분 0.00%를 보고했습니다. 해당 신고서에는 어떠한 신고인에게도 단독 또는 공동의 의결권이나 처분권이 부여되지 않음으로 표시되어 있습니다.

지분 비율의 계산은 발행인이 보고한 90,376,972주의 보통주 유통주식수를 기준으로 합니다. 제출 문서에는 이하 서명인들이 향후 수정서를 서로를 대신하여 제출하기로 합의하고 각자의 공시 책임을 확인하는 공동 제출 진술서가 포함되어 있습니다.

Trois déclarants ont déposé un Schedule 13G/A pour Allakos Inc. (actions ordinaires). Les déclarants — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; et David Kroin — déclarent aucune action détenue à titre bénéficiaire et 0,00% de propriété de la catégorie. La déclaration indique qu'aucun pouvoir de vote ni de disposition, ni en propre ni partagé, n'est attribué à l'un quelconque des déclarants.

Le calcul du pourcentage est basé sur le nombre d'actions ordinaires en circulation communiqué par l'émetteur, soit 90.376.972. Le dépôt comprend une déclaration conjointe par laquelle les soussignés conviennent de déposer à l'avenir des amendements au nom les uns des autres et confirment leur responsabilité quant à leurs divulgations respectives.

Drei meldepflichtige Personen reichten ein Schedule 13G/A für Allakos Inc. (Common Stock) ein. Die Meldenden — Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; und David Kroin — geben keine zuvorteilhaft gehaltenen Aktien und 0,00% Eigentum an der Aktienklasse an. Die Erklärung weist aus, dass keine alleinige oder gemeinsame Stimm- oder Verfügungsgewalt einer meldenden Person zugerechnet wird.

Die Prozentberechnung basiert auf der vom Emittenten gemeldeten Anzahl von 90.376.972 ausstehenden Stammaktien. Die Einreichung enthält eine gemeinsame Einreichungserklärung, in der die Unterzeichner vereinbaren, künftige Nachträge füreinander einzureichen und die Verantwortung für ihre jeweiligen Angaben bestätigen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:08/14/2025
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:08/14/2025
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:08/14/2025
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of August 14, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 90,376,972 Common Stock outstanding as of May 5, 2025 according to the issuer's 10-Q filed with the SEC on May 7, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

Who filed the Schedule 13G/A for Allakos (ALLK)?

Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin are the reporting persons listed.

How many Allakos (ALLK) shares do the reporting persons beneficially own?

The reporting persons state they beneficially own 0 shares, representing 0.00% of the class.

What voting or dispositive powers do the filers claim for ALLK shares?

The filers report no sole or shared voting power and no sole or shared dispositive power over Allakos common stock.

What share count was used to calculate the ownership percentage for ALLK?

The percentage is calculated using the issuer's reported common share total of 90,376,972 shares outstanding.

Does the filing indicate a coordinated group or control intent for ALLK?

The filing includes a joint filing statement to manage amendment responsibilities, but reports no ownership or control by the filers.
Allakos

NASDAQ:ALLK

ALLK Rankings

ALLK Latest News

ALLK Latest SEC Filings

ALLK Stock Data

29.63M
88.59M
Research and Development in Biotechnology
Pharmaceutical Preparations
Link
US
SAN CARLOS